PRESS RELEASE published on 10/03/2024 at 14:00, 2 years 1 month ago Prof. Dr. Wiltrud Treffenfeldt leaves Supervisory Board of BRAIN Biotech AG for personal reasons Prof. Dr. Wiltrud Treffenfeldt resigns from Supervisory Board of BRAIN Biotech AG for personal reasons. Search for successor initiated. Company specializes in industrial biotechnology solutions Biotechnology Resignation Supervisory Board Successor BRAIN Biotech AG
BRIEF published on 09/20/2024 at 19:55, 2 years 2 months ago BRAIN Biotech AG Secures EUR 128.88 Million Deal with Royalty Pharma Non-dilutive Financing BRAIN Biotech AG Royalty Monetization Investigational Compound Industrial Enzymes
BRIEF published on 09/20/2024 at 19:55, 2 years 2 months ago BRAIN Biotech AG conclut un accord de 128,88 millions d'euros avec Royalty Pharma BRAIN Biotech SA Financement Non Dilutif Monétisation Des Redevances Composé Expérimental Enzymes Industrielles
BRIEF published on 09/20/2024 at 19:52, 2 years 2 months ago BRAIN Biotech AG Secures Royalty Monetization Deal Worth Up to EUR 128.88 Million BRAIN Biotech Royalty Monetization Deucrictibant Royalty Pharma Hereditary Angioedema
BRIEF published on 09/20/2024 at 19:52, 2 years 2 months ago BRAIN Biotech AG conclut un accord de monétisation de redevances d'une valeur maximale de 128,88 millions d'euros CERVEAU Biotechnologie Royalty Pharma Monétisation Des Redevances Déucritibant Œdème De Quincke Héréditaire
PRESS RELEASE published on 09/20/2024 at 19:50, 2 years 2 months ago BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator BRAIN Biotech AG concludes a major pharma compound transaction valued up to EUR 128.88 million, monetizing royalty rights with Royalty Pharma for investigational compound deucrictibant from BioIncubator BRAIN Biotech AG Pharma Royalty Pharma Compound Transaction BioIncubator
PRESS RELEASE published on 09/20/2024 at 19:47, 2 years 2 months ago EQS-Adhoc: BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma BRAIN Biotech AG Deucrictibant Royalty Pharma Royalty Monetization Deal EUR 128.88 Million
BRIEF published on 08/29/2024 at 07:35, 2 years 2 months ago BRAIN Biotech AG Reports Robust Cash Position and Forecasts Growth Financial Results Cash Position Growth Forecast BRAIN Biotech AG BioProducts
BRIEF published on 08/29/2024 at 07:35, 2 years 2 months ago BRAIN Biotech AG annonce une solide position de trésorerie et prévoit une croissance Résultats Financiers BioProduits BRAIN Biotech SA Prévisions De Croissance Situation De Trésorerie
PRESS RELEASE published on 08/29/2024 at 07:30, 2 years 2 months ago BRAIN Biotech AG presents strong cash position with its 9M reporting and is forecasting good sequential growth in the final quarter of the business year BRAIN Biotech AG reports strong cash position for 9M period, forecasting growth in Q4 FY 23/24. BioProducts segment turnover slightly up, BioScience segment facing decline Cash Position BRAIN Biotech AG BioScience BioProducts Forecasting
Published on 11/20/2026 at 15:00, 20 hours 11 minutes ago Jaguar Health, Inc. Announces Reverse Stock Split
Published on 11/20/2026 at 14:50, 20 hours 21 minutes ago Proposed Issue Of Payment-In-Kind Interest Shares Under Convertible Debenture
Published on 11/20/2026 at 14:00, 21 hours 11 minutes ago Dateline appoints Tony Ferguson as Acting Chairman
Published on 11/20/2026 at 13:30, 21 hours 41 minutes ago Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
Published on 11/20/2026 at 13:30, 21 hours 41 minutes ago Alset AI Closes Non-Brokered Private Placement Offering
Published on 11/20/2026 at 23:45, 11 hours 25 minutes ago APEC CEO Summit 2026 Concludes Successfully in Shenzhen
Published on 11/20/2026 at 22:39, 12 hours 31 minutes ago ABIVAX: Abivax publie une déclaration concernant le rapport d'un vendeur à découvert
Published on 11/20/2026 at 21:36, 13 hours 34 minutes ago EQS-Adhoc: Global Health Care AG: Board of Directors proposes sale of milon stake based on an equity value of EUR 23.3 million – subscription right for all shareholders
Published on 11/20/2026 at 20:49, 14 hours 21 minutes ago E-PANGO: Jugement du Tribunal Judiciaire de Paris relatif au contentieux avec le groupement RIVP-HENEO-HSF
Published on 11/20/2026 at 18:34, 16 hours 36 minutes ago Déclaration hebdomadaire d'opérations effectuées du 16 au 20 novembre 2026
Published on 11/20/2026 at 18:34, 16 hours 36 minutes ago Disclosure of transactions in own shares from November 16 to November 20, 2026
Published on 11/20/2026 at 17:35, 17 hours 36 minutes ago Guillemot Corporation S.A. | Déclaration hebdomadaire des transactions sur actions propres du 16 au 20 novembre 2026
Published on 11/20/2026 at 17:35, 17 hours 36 minutes ago Guillemot Corporation S.A. | Weekly report share buyback from November 16 to November 20, 2026
Published on 11/19/2026 at 19:00, 1 day 16 hours ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR